Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
30 August 2022 | Story André Damons | Photo André Damons
UFS Nuclear Medicine
The team of doctors in the Department of Nuclear Medicine behind the success story are, from the left (standing): Dr Osayande Evbuomwan, nuclear medicine specialist and Senior Lecturer; Dr Gerrit Engelbrecht, Clinical Head of the Department of Nuclear Medicine at the UFS; and Dr Walter Endres, nuclear medicine registrar. In front is Dr Tebatso Tebeila, nuclear medicine registrar.

The University of the Free State (UFS) Department of Nuclear Medicine is proud to announce the successful treatment outcome of a patient with metastatic castrate-resistant prostate cancer (MCRPC) – an advanced stage of prostate cancer – by using Lutetium 177 PSMA (Lu-177 PSMA) therapy. This was initially a case of advanced stage prostate cancer, which had failed first-line chemotherapy, leaving little or no other treatment options.

This is a proud and happy moment for the department and the UFS, which started this treatment just over a year ago. The university and the Free State province are now joining other South African medical universities, such as the University of Pretoria, and other provinces in using this method to treat MCRPC patients. Lutetium 177 PSMA (Lu-177 PSMA) therapy is used on MCRPC patients who are not eligible for chemotherapy or have failed first- or second-line chemotherapy.

Dr Gerrit Engelbrecht, Clinical Head of the Department of Nuclear Medicine at the UFS, says the department is proud to be able to offer this treatment option to some of these patients. “It is a big win for the Free State and our oncology patients to be able to offer these expert services.” The UFS and Universitas Academic Hospital have now been able to join up with other academic institutions and hospitals in other provinces to offer these services. So far, three patients have been offered this therapeutic option, with the third patient currently undergoing his treatment.

Funds and equipment for proper treatment selection are needed

The expertise is no longer an issue for the UFS, as Dr Osayande Evbuomwan, nuclear medicine specialist and consultant, was trained and exposed to this therapy at the University of the Witwatersrand during his training as a nuclear medicine resident. Current registrars in the Department of Nuclear Medicine at the UFS are also being trained in the application of this treatment modality. However, proper patient selection is key in the management of these cases with Lu 177 PSMA. Without a PET/CT camera, it is challenging to appropriately select the patients who are most likely to respond to this therapy. This is an example of how PET/CT is crucial in the management and monitoring of oncology patients.

Both Drs Engelbrecht and Evbuomwan hope that the training of more registrars will increase their department’s capacity to treat more patients. They also hope that funds will be made available to acquire a much-needed PET/CT camera, which will greatly assist them in identifying the correct patients in need of this treatment. 

With the permission of the patient, the images above show the dramatic treatment response following Lu-177 PSMA therapy. The images on the left show widespread bone disease from the prostate cancer, including the skull. The images on the right show the dramatic response after completing four cycles of Lu 177 PSMA, with the normal excretion of the radiotracer seen in the liver, kidneys, and bladder.


Treatment puts the department, UFS, and hospital on the map

According to Dr Evbuomwan, the ability to administer this treatment puts the department, the UFS, and the hospital on the map, alongside other top universities within and outside the country. Says he: “It also creates an avenue for us to gather data for training, research purposes, and publications. We are now able to offer a promising, safe, and highly efficacious therapy for patients with MCRPC in the Free State. Some of these patients will no longer have to travel to other provinces to receive this treatment.”


“We are also well aware that not every patient will respond this way; however, proper patient selection is key in identifying responders – an area that is still being researched. We also do not know how long these patients will have their disease under control after the treatment. Nuclear medicine’s greatest cancer therapy success story is the treatment of well-differentiated thyroid cancer with radioactive iodine.” 

“After treatment, most of these patients remain cancer-free for a very long period of time, if not for life. With continuing research in the field of MCRPC radioligand therapy, we aim to improve the treatment modality, hopefully getting it to the success level of thyroid cancer therapy.”

 

News Archive

First Rand Foundation contributes funding towards students with disabilities
2017-01-02

 Description: First Rand Foundation Tags: First Rand Foundation

Photo: iStock

Bursary funding for eight students with disabilities at the University of the Free State was recently approved by the First Rand Foundation. The grant of R2 497 440 will be paid over three years: R800 000 (2016/17), R824 000 (2017/18), and R873 440 (2018/19).

This grant from the First Rand Tertiary Education Fund is a result of the negotiations between the UFS Office for Institutional Advancement and the First Rand Foundation (FRF).

Qualifying students with disabilities will be encouraged to apply for bursaries according to criteria and requirements set by the First Rand Foundation. The selection process will be handled by a panel from the UFS. The Centre for Universal Access and Disability Support (CUADS) at the UFS will be instrumental in the process of identifying students with disabilities who meet the criteria and requirements for funding.

CUADS already have a system in place to support students with disabilities in their studies and during exams. Students also have access to specialised exam and test venues for alternative test and exam procedures, as well as computer facilities.

Specialised support services include an amanuensis (scribe) service during tests and exams, accommodating extra time, individual tutor sessions provided in collaboration with the Centre for Teaching and Learning, South African Sign Language interpreter coordination, provision of accessible study material, and individual disability support.

 

“The centre aims to ensure that the university increasingly becomes a universally accessible environment that is welcoming and accepting to people with diverse abilities.”

According to Martie Miranda, Head of CUADS, the centre aims to ensure that the university increasingly becomes a universally accessible environment that is welcoming and accepting to people with diverse abilities. “Therefore disability awareness training and advocacy within the UFS, and specifically among staff members, is one of our priorities,” she said.

According to Thandeka Rantsi from the FRF, the company will furthermore support students in CUADS with regards to the needs ensuing from the #feesmustfall protests. “Exactly R34 000 was approved by the FRF for 14 students towards residence and meal expenses, as well as scribe and reader assistance during additional assessments,” she said.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept